SUMMARY A sensitive immunocytochemical technique was developed to detect a 170 000 dalton cell membrane glycoprotein (P-gp) in cell lines resistant to vincristine and vinblastine with varying degrees of resistance. P-gp was shown very clearly using the C219 monoclonal antibody and immunocytochemical detection with either antialkaline phosphate or peroxidase-antiperoxidase with silver gold intensification. There was good correlation between the results obtained with immunocytochemical detection of P-gp in single cells and Western blot analysis.
The development of multidrug resistance is associated with increased expression of a gene, or family of genes, encoding a 170 000 dalton glycoprotein, P-glycoprotein (P-gp).'-3 Several lines of evidence suggest that P-gp is the energy dependent drug efflux pump responsible for multidrug resistance in cells selected in culture. The role ofP-gp in the development of clinical drug resistance needs to be investigated. 45 Increased concentrations of P-gp have been shown in multidrug resistant cultured cell lines and human tumours by Western blot analysis of cell membrane preparations using monoclonal antibodies specifically developed for P-gp.8 This method relies on the homogenisation and extraction of cell membranes from whole tumour tissue and would almost certainly fail to detect a multidrug resistant population that comprised only a small percentage of the tumour cells. In contrast, the immunocytochemical detection of P-gp works at the single cell level, which potentially could achieve the spatial resolution and degree of sensitivity that is required to investigate the development and emergence of multidrug resistance in heterogeneous tumours. We therefore developed a relatively simple immunocytochemical technique, using the C-219 monoclonal antibody to detect P-gp in single cells, and compared the sensitivity of this method with Western blot analysis of P-gp.
Accepted for publication 19 January 1989 Material and methods Human lymphoid cell lines (CCRF-CEM) with varying degrees of resistance (0-1000 ng/ml) to vinblastine and vincristine were selected for growth in the presence of increasing concentrations of drug.6 The CEM/VLB'" and CEM/VLB'°°°are vinblastine resistant sublines which grow in the presence of 100 ng/ml and 1000 ng/ml vinblastine, respectively. These lines were cloned and made available for this work by Dr Friedlander, Bell, Leary, Davey nique of detection of P-gp was tested on cytospins prepared from samples of blood, or bone marrow from patients with acute leukaemia and myeloma. The preliminary results indicate that the technique is well suited to the testing ofclinical samples and permits the detection of P-gp in relatively small numbers of cells that would almost certainly be missed using Western blot analysis. (fig 4) .
Discussion
Drug resistance has become a major obstacle to the successul management of cancer and accounts for the failure of chemotherapy to cure or induce long term remissions in most patients with advanced cancer.'2 The phenomenon of multidrug resistance following exposure ofa cell population to a single agent has been extensively studied using in vitro models, and there is growing evidence to show that it also occurs during the course of clinical chemotherapy.3 6 7 8 13 14 Prospective studies are needed to determine how frequently clinical drug resistance is associated with the increased expression of P-gp in human tumours. Such studies have used either Northern blotting to detect mRNA, or Western blotting to detect P-gp in tumour samples that have been homogenised and extracted. These methods sacrifice the resolution and sensitivity that could be potentially achieved with either in situ hybridisation or immunocytochemical detection of P-gp in single cells. This is essential in the examination of heterogeneous tissues where the multidrug resistant cell population may initially comprise only a small percentage of the tumour cells, as exemplified by our preliminary results in screening peripheral blood and bone marrow obtained from patients with leukaemia8 and myeloma.
Our studies indicate a good correlation between the results achieved with immunocytochemistry and Western blot analysis in detecting the presence ofP-gp in a homogeneous cell population with levels of resistance of > 40 ng/ml for vinblastine or vincristine. It is, however, impossible to quantitate accurately the degree of resistance according to the extent of immunostaining as cells resistant to greater than 100 ng/ml vincristine/vinblastine have a very similar appearance to cells resistant to 1000 ng/ml. The immunocytochemical technique is nevertheless simple to perform and has the advantage of detecting P-gp in relatively small numbers of cells that could be missed using Western blot analysis. Studies are underway to determine whether the immunocytochemical detection of P-gp in human tumours correlates with multidrug resistance, and to define its clinical role. '5 
